Eric Lefkofsky is a Chicago based serial entrepreneur and philanthropist. He and Brad Keywell founded Tempus in 2015. Tempus is a technology company that has built an operating system to battle cancer. Tempus redefines genomic data in a clinical setting. The centralized system allows physicians to learn from previous cancer patients and find more effective treatment options for their patients.
The startup is expanding rapidly by adding 30 employees monthly to its existing 400 employees. Six months after Tempus raised a $70 million round; it raised $80 million in new funding on March. The funding brings the company’s total amount increased to $210 million with new investors including Kinship Trust Company and T. Rowe Price, along with existing investors New Enterprise Associates and Revolution Growth.
“Tempus was born out of frustration with a health care system that too often let powerful data and real-world evidence go to waste,” said Eric Lefkofsky, co-founder and CEO at Tempus. “Given the breadth and scale of our current data set, we’re in a unique position to help usher in an era of precision medicine to support patients battling diseases.”
Tempus takes on cancer by gathering information on the patient’s clinical and molecular data and creating a repository cancer patients’ data in structured form. They generate molecular data by sequencing patients’ DNA and RNA to uncover more personalized treatment. This would help prolong the lifespan of cancer patients.
The company works in collaboration with cancer research hospitals like the Mayo Clinic, Northwestern University, the University of Chicago, and the University of Michigan, the Cleveland Clinic, Duke University School of Medicine, the UC Davis Comprehensive Cancer Center and Knight Cancer Institute at the OHSU. It currently works with nearly half of all Academic Medical Centers in the United States.
“I think the traction we have had with everybody in the industry has been kind of amazing,” Lefkofsky said. “We’re in the midst of one of the most significant paradigm shifts of our time.”
Millions of men all over the world get diagnosed with prostate cancer every year, and the number of people who get diagnosed with it in the United States is higher than it has ever been. Even though this is such a common form of cancer, many men don’t the intricacies of protecting themselves, and the course of treatments that they need to take when they have been diagnosed with it.
Mitt Romney, the former presidential nominee for the Republican Party came forward to tell the people that he had been diagnosed with prostate cancer, and had to opt for a surgery to remove a tumor that has started growing in the early month of 2017. This announcement helped millions of men realize that there is hope for those who have been diagnosed with prostate cancer, and also emphasized for getting timely checkups every year. Romney’s surgery was incredibly successful and was performed by some of the most well-known doctors in the field.
Romney isn’t the first political member who has come forward to state that he has undergone surgery for prostate cancer. Several others in the past like Colin Powell and Walter Reed have undergone surgery for prostate cancer.
Dr. David Samadi, a well-known Urologist and Chief of Surgery practicing in Lenox Hill Hospital outlined the various intricacies of Prostate Cancer in a recent interview that he conducted. In the article, he laid out the age group of men that are most likely to develop prostate cancer. According to his statement, prostate cancer occurs in men that are over the age of sixty-five. However, there have been certain instances where men have reported having prostate cancer under the age of forty.
When men are diagnosed with prostate cancer, one of the first questions that are generally asked is the course of treatment that they will now have to take. One of the options that are presented to them is undergoing radiation therapy, while the second is undergoing surgery. Both options come with their own set of pros and cons which can help the person making the decision. Normally, the best thing to do in this instance according to Dr. Samadi asks your oncologist what is the best option. He or she will be able to let you know what the best course would be, depending on the prognosis of cancer and what stage it is in.